To harness its undoubted expertise in drug development, Australia requires a coordinating entity to ensure efficiency in translation of advances relating to small molecule pharmaceuticals. This entity will mimic the role of the major pharmaceutical companies in the modern network model of drug development.
Established under THD project, the Virtual Pharma Network (VPN) is an expert panel in the pharmaceutical area that mimics the pharma capability in fully integrated pharmaceutical companies, providing a coordinating focus for drug development programs and an aggregation of existing drug development expertise and capability. This panel can guide researchers on drug development with an emphasis on translational and commercialisation outcomes and will also provide a vehicle for closer alliances between researchers and industry.
Additional details on Virtual Pharma are available here